The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?
File(s)10.1007_s11011-017-0077-2.pdf (977.51 KB)
Published version
Author(s)
Morris, G
Puri, BK
Frye, RE
Type
Journal Article
Abstract
The conceptualisation of autistic spectrum disorder and Alzheimer’s disease has undergone something of a paradigm shift in recent years and rather than being viewed as single illnesses with a unitary pathogenesis and pathophysiology they are increasingly considered to be heterogeneous syndromes with a complex multifactorial aetiopathogenesis, involving a highly complex and diverse combination of genetic, epigenetic and environmental factors. One such environmental factor implicated as a potential cause in both syndromes is aluminium, as an element or as part of a salt, received, for example, in oral form or as an adjuvant. Such administration has the potential to induce pathology via several routes such as provoking dysfunction and/or activation of glial cells which play an indispensable role in the regulation of central nervous system homeostasis and neurodevelopment. Other routes include the generation of oxidative stress, depletion of reduced glutathione, direct and indirect reductions in mitochondrial performance and integrity, and increasing the production of proinflammatory cytokines in both the brain and peripherally. The mechanisms whereby environmental aluminium could contribute to the development of the highly specific pattern of neuropathology seen in Alzheimer’s disease are described. Also detailed are several mechanisms whereby significant quantities of aluminium introduced via immunisation could produce chronic neuropathology in genetically susceptible children. Accordingly, it is recommended that the use of aluminium salts in immunisations should be discontinued and that adults should take steps to minimise their exposure to environmental aluminium.
Date Issued
2017-07-27
Date Acceptance
2017-07-19
Citation
Metabolic Brain Disease, 2017, 32 (5), pp.1335-1355
ISSN
0885-7490
Publisher
Springer Verlag
Start Page
1335
End Page
1355
Journal / Book Title
Metabolic Brain Disease
Volume
32
Issue
5
Copyright Statement
© The Author(s) 2017. This article is an open access publication
License URL
Subjects
Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
Neurosciences
Neurosciences & Neurology
Brain
Neuropathology
Aluminum
Alzheimer disease
Autism spectrum disorder
Autoimmunity
AUTISM SPECTRUM DISORDERS
TOLL-LIKE RECEPTORS
CENTRAL-NERVOUS-SYSTEM
NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE
DORSOLATERAL PREFRONTAL CORTEX
INFLAMMATORY DENDRITIC CELLS
CYTOKINE GENE POLYMORPHISMS
INNATE IMMUNE-RESPONSE
ALZHEIMERS-DISEASE AD
HEPATITIS-B-VACCINE
Publication Status
Published